

**TABLE 1: RECOMMENDED MEASURES for  
NATIONAL VOLUNTARY CONSENSUS STANDARDS for AMBULATORY CARE  
USING CLINICALLY ENRICHED ADMINISTRATIVE DATA**

Measure Number, Title and IP Owner <sup>1</sup>	Measure Description	Data Level
<b>ASTHMA AND RESPIRATORY ILLNESS</b>		
<b>EC-234-08<sup>2</sup></b> Asthma-Short-Acting Beta Agonist Inhaler for Rescue Therapy © Active Health	Percentage of patients with asthma who have a refill for a short acting beta agonist in the past 24 months	LEVEL 2 (encounter and pharmacy) alternative LEVEL 3 (exclusions)
<b>EC-016-08</b> Use of Spirometry Testing in the Assessment and Diagnosis of COPD © NCQA	This measure assesses the percentage of members 40 years of age and older with a new diagnosis or newly active chronic obstructive pulmonary disease (COPD) who received appropriate spirometry testing to confirm the diagnosis.	LEVEL 2 (visit/diagnosis and procedure)
<b>EC- 227-08</b> High Risk for Pneumococcal Disease - Pneumococcal Vaccination © Active Health	Percentage of patients age 5-64 with a high risk condition or age 65 years and older who received the pneumococcal vaccine	LEVEL 3 (patient data) only
<b>BONE AND JOINT CONDITIONS</b>		
<b>EC-089-08</b> New Rheumatoid Arthritis Baseline ESR or CRP within Three Months © Resolution Health	This measure identifies adult patients newly diagnosed with rheumatoid arthritis during the first 8 months of the measurement year who received erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) lab tests either 4 months (3 months + 1-month grace period) before or after the initial diagnosis.	LEVEL 2 - (visit/diagnosis and lab)
<b>EC-060-08</b> Rheumatoid Arthritis Annual ESR or CRP © Resolution Health	This measure identifies adult patients with a history of rheumatoid arthritis who have received erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) lab tests during the measurement year.	LEVEL 2 - (visit/diagnosis and lab)
<b>EC-056-08</b> Rheumatoid Arthritis New DMARD Baseline Serum Creatinine © Resolution Health	This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline serum creatinine testing within 90 days before to 14 days after the new start of methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, cyclosporine, or cyclophosphamide during the measurement year.	LEVEL 2 (visit/diagnosis and pharmacy and lab)
<b>EC-057-08</b> Rheumatoid Arthritis New DMARD Baseline Liver Function Test © Resolution Health	This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline liver function testing (AST or ALT) within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, cyclosporine or cyclophosphamide during the measurement year.	LEVEL 2 (visit/diagnosis and pharmacy and lab)

<sup>1</sup> Intellectual property owner and copyright holder. ALL RIGHTS RESERVED.

<sup>2</sup> Candidate standard numbers assigned by NQF during the consensus process.

Measure Number, Title and IP Owner <sup>1</sup>	Measure Description	Data Level
<b>EC-059-08</b> Rheumatoid Arthritis New DMARD Baseline CBC © Resolution Health	This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline complete blood count (CBC) testing within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, oral gold, cyclosporine, or cyclophosphamide during the measurement year	LEVEL 2 (visit/diagnosis and pharmacy and lab)
<b>EC-049-08</b> Hydroxychloroquine Annual Eye Exam © Resolution Health	This measure identifies the percentage of patients with Rheumatoid Disease who received hydroxychloroquine during the measurement year and had a fundoscopic examination during the measurement year or in the year prior to the measurement year	LEVEL 2 (visit/diagnosis and pharmacy)
<b>EC-079-08</b> Methotrexate: LFT within 12 Weeks © Resolution Health	This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a liver function test (LFT) in the 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim.	LEVEL 2 (visit/diagnosis and pharmacy and lab)
<b>EC-080-08</b> Methotrexate: CBC within 12 Weeks © Resolution Health	This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a CBC test within 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim.	LEVEL 2 (visit/diagnosis and pharmacy and lab)
<b>EC-081-08</b> Methotrexate: Creatinine within 12 Weeks © Resolution Health	This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a serum creatinine test in the 120 days (3 months + 1 month grace period) after the earliest observed methotrexate prescription claim.	LEVEL 2 (visit/diagnosis and pharmacy and lab)
<b>EC-283-08</b> Osteoporosis-Use of Pharmacologic Treatment © Active Health	Percentage of patients who have osteoporosis and are on osteoporosis therapy.	LEVEL 2 (visit/diagnosis and pharmacy)
<b>EC-213-08</b> Steroid Use - Osteoporosis Screening © Active Health	Percentage of patients age 18 and older who have been on chronic steroids for at least 180 days in the past 9 months that have had a bone density evaluation to check for osteoporosis.	LEVEL 2 (visit/diagnosis, pharmacy and imaging)
<b>EC-281-08</b> Osteopenia and Chronic Steroid Use – Treatment to prevent Osteoporosis © Active Health	Percentage of patients, who are female and 55 years and older or male and 50 years and older, who have a diagnosis of osteopenia and are on long-term steroids (> 6 months) and who are on osteoporosis therapy.	LEVEL 3 (exclusions)
<b>CANCER SCREENING AND SURVEILLANCE</b>		
<b>EC-028-08</b> Annual Cervical Cancer	This measure identifies women age 12 to 65	LEVEL 2

Measure Number, Title and IP Owner <sup>1</sup>	Measure Description	Data Level
Screening for High Risk Patients © Resolution Health	diagnosed with cervical dysplasia (CIN 2), cervical carcinoma-in-situ, or HIV/AIDS prior to the measurement year, and who still have a cervix, who had a cervical CA screen during the measurement year.	(visit/diagnosis and lab)
<b>EC-240-08</b> Breast Cancer-Cancer Surveillance © Active Health	Percentage of female patients with breast cancer who had breast cancer surveillance in the past 12 months	LEVEL 2 (visit/diagnosis and imaging)
<b>EC-007-08</b> Follow-Up after Initial Diagnosis and Treatment of Colorectal Cancer: Colonoscopy © Health Benchmarks	To ensure that all eligible members who have been newly diagnosed and resected with colorectal cancer receive a follow-up colonoscopy within 15 months of resection.	LEVEL 2 (visit/diagnosis and lab or procedure)
<b>EC-248-08</b> Prostate Cancer – Cancer Surveillance © Active Health	Percentage of males with prostate cancer that have had their PSA monitored in the past 12 months	LEVEL 2 (visit/diagnosis and lab)
<b>CARDIOVASCULAR DISEASE</b>		
<b>EC-071-08</b> Post MI: ACE Inhibitor or ARB Therapy © Resolution Health	This measure identifies patients with ST elevation MI (STEMI), or non-ST elevation MI (NSTEMI) plus a history of hypertension, heart failure and/or diabetes prior to the measurement year who are taking an ACEI or an ARB during the measurement year.	LEVEL 2 (visit/diagnosis and pharmacy)
<b>EC-208-08</b> MI-Use of Beta Blocker Therapy © Active Health	Percentage of patients who had a myocardial infarction (MI) and are taking a beta blocker	LEVEL 2 (visit/diagnosis and pharmacy) Alternative Level 3 (side effects)
<b>EC-054-08</b> Stent Drug-Eluting Clopidogrel © Resolution Health	This measure identifies patients undergoing percutaneous coronary intervention (PCI) with placement of a drug-eluting intracoronary stent during the first 9 months of the measurement year, who filled a prescription for clopidogrel in the 3 months following stent placement	LEVEL 2 (procedure and pharmacy)
<b>EC-272-08</b> Secondary Prevention of Cardiovascular Events- Use of Aspirin or anti-platelet therapy © Active Health	Percentage of patients with ischemic vascular disease (IVD) that are taking aspirin or an anti-platelet agent	LEVEL 3 (OTC medication)
<b>EC-202-08</b> Heart Failure - Use of ACE Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) Therapy © Active Health	Percentage of patients with CHF that are on an ACE-I or ARB	LEVEL 2 (visit/diagnosis and pharmacy)
<b>EC-215-08</b> Congestive Heart Failure-Use of a Beta Blocker © Active Health	Percentage of adult patients with congestive heart failure (CHF) that are on a beta blocker	LEVEL 2 (visit/diagnosis and pharmacy)
<b>EC-083-08</b> New Atrial Fibrillation: Thyroid Function Test © Resolution Health	This measure identifies patients with new-onset atrial fibrillation during the measurement year who have had a thyroid function test 6 weeks before or	LEVEL 2 (visit/diagnosis and lab)

Measure Number, Title and IP Owner <sup>1</sup>	Measure Description	Data Level
	after the diagnosis of atrial fibrillation	
<b>EC-244-08</b> Atrial Fibrillation - Warfarin Therapy © Active Health	Percentage of adult patients with atrial fibrillation and major stroke risk factors on warfarin	LEVEL 2 (visit/diagnosis and pharmacy)
<b>EC-256-08</b> Male Smokers or Family History of Abdominal Aortic Aneurysm (AAA) Screening for AAA © Active Health	Percentage of men age 65-75 years with history of tobacco use or men age 60 yrs and older with a family history of abdominal aortic aneurysm who were screened for AAA	LEVEL 3 (family history and smoking history)
<b>EC-099-08</b> [hypertension] patients with a serum creatinine in the last 12 months © Ingenix	This measure identifies patients with hypertension (HTN) that had a serum creatinine in last 12 reported months	LEVEL 2 (visit/diagnosis and lab)
<b>EC-037-08</b> Deep Vein Thrombosis Anticoagulation >= 3 Months - ©Resolution Health	This measure identifies patients with deep vein thrombosis (DVT) on anticoagulation for at least 3 months after the diagnosis.	LEVEL 2 (visit/diagnosis and pharmacy)
<b>EC-061-08</b> Pulmonary Embolism Anticoagulation >= 3 Months - ©Resolution Health	This measure identifies patients with pulmonary embolism (PE) on anticoagulation for at least 3 months after the diagnosis.	LEVEL 2 (visit/diagnosis and pharmacy)
<b>CHILD HEALTH</b>		
<b>EC-053-08</b> Tympanostomy Tube Hearing Test © Resolution Health	This measure identifies the percentage of patients age 2 through 12 years with OME who received tympanostomy tube(s) insertion during the measurement year and had a hearing test performed within 6 months prior to the initial tube placement.	LEVEL 2 (visit/diagnosis/ procedure and hearing test)
<b>CHRONIC KIDNEY DISEASE</b>		
<b>EC-006-08</b> Chronic Kidney Disease: Monitoring Parathyroid Hormone (PTH) © Health Benchmarks	To ensure that members with chronic kidney disease, who are not undergoing dialysis, are monitored for PTH levels at least once annually	LEVEL 2 (visit/diagnosis and lab)
<b>EC-012-08</b> Chronic Kidney Disease: Monitoring Calcium © Health Benchmarks	To ensure that members with chronic kidney disease, but who are not on dialysis, are monitored for blood calcium levels at least annually	LEVEL 2 (visit/diagnosis and lab)
<b>EC-005-08</b> Chronic Kidney Disease: Monitoring Phosphorous © Health Benchmarks	To ensure that members with chronic kidney disease but who are not on dialysis are monitored for blood phosphorous levels at least once annually.	LEVEL 2 (visit/diagnosis and lab)
<b>EC-251-08</b> Chronic Kidney Disease – Lipid Profile Monitoring © Active Health	Percentage of patients with chronic kidney disease that have been screened for dyslipidemia with a lipid profile	LEVEL 2 (visit/diagnosis and lab)
<b>EC-252-08</b> Chronic Kidney Disease with LDL Greater than or equal to 130 – consider adding a lipid lowering agent © Active Health	Percentage of patients with chronic kidney disease and an LDL greater than or equal to 130mg/dl that have a current refill for a lipid lowering agent	LEVEL 3 (lab result)
<b>EC-238-08</b> Non-Diabetic	Percentage of patients with proteinuria that have a	LEVEL 3

Measure Number, Title and IP Owner <sup>1</sup>	Measure Description	Data Level
Nephropathy – consider adding and ACEI or ARB © Active Health	current refill for an angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)	(lab result)
<b>DIABETES</b>		
<b>EC-096-08</b> Adult(s) with diabetes that had a serum creatinine in the last 12 reported months © Ingenix	This measure identifies adults with diabetes mellitus that had a serum creatinine test in last 12 reported months.	LEVEL 2 (visit/diagnosis and lab)
<b>EC-095-08</b> Adults(s) taking insulin with evidence of self-monitoring blood glucose testing © Ingenix	This measure identifies patients with diabetes mellitus taking insulin that had evidence of self-monitoring blood glucose testing in last 12 reported months.	LEVEL 2 (visit/diagnosis and pharmacy)
<b>EC-274-08</b> Primary prevention of cardiovascular events in diabetics older than 40 years – Use of aspirin or antiplatelet therapy © Active Health	Percentage of adult patients with diabetes treated with aspirin or an antiplatelet agent.	LEVEL 3 (OTC medication, lab results)
<b>EC-231-08</b> Diabetes with LDL greater than 100 – Use of a lipid lowering agent © Active Health	Percentage of adult patients with diabetes mellitus and an LDL value greater than 100 mg/dL with a current refill for a lipid lowering agent	LEVEL 3 (lab result)
<b>EC-232-08</b> – Diabetes with Hypertension or Proteinuria - Use of an ACE Inhibitor or ARB © Active Health	Percentage of patients with diabetes and hypertension or proteinuria that have a current refill for an angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)	LEVEL 3 (lab result)
<b>EC-262-08</b> Diabetes and elevated HbA1c – Use of diabetes medications © Active Health	Percentage of patients 18- 75 years with diabetes and an elevated HbA1c that are receiving diabetic treatment (e.g., Metformin)	LEVEL 3 (lab result)
<b>EC-013-08</b> Comprehensive diabetes care: HgA1c control (<8%) © NCQA	The percentage of members 18 - 75 years of age with diabetes (type 1 and type 2) who had HbA1c control (<8.0%).	LEVEL 3 (lab result)
<b>GASTROESOPHAGEAL: REFLUX DISEASE (GERD)</b>		
<b>EC-239-08</b> GERD - Upper Gastrointestinal Study in Adults with Alarm Symptoms © Active Health	Percentage of patients with gastroesophageal reflux disease (GERD)with alarm symptoms and who have had an upper gastrointestinal study	LEVEL 2 (visit/diagnosis and procedure); alternative LEVEL 3 (use of patient derived data and lab results)
<b>GYNECOLOGY</b>		
<b>EC-002-08</b> Appropriate Work Up Prior To Endometrial Ablation Procedure© Health Benchmarks	To ensure that all women have endometrial sampling performed before undergoing an endometrial ablation.	LEVEL 2 (procedure and lab)
<b>HEPATITIS AND LIVER DISEASE</b>		
<b>EC-285-08</b> Chronic Liver Disease - Hepatitis A Vaccination © Active Health	Percentage of patients with chronic liver disease who have received a hepatitis A vaccine	LEVEL 3 (Patient data on history of

Measure Number, Title and IP Owner <sup>1</sup>	Measure Description	Data Level
		vaccination)
<b>EC-046-08</b> Hepatitis C: Viral Load Test © Resolution Health	This measure identifies the percentage of patients with Hepatitis C (HCV) who began HCV antiviral therapy during the measurement year and had HCV Viral Load testing prior to initiation of antiviral therapy.	LEVEL 2 (visit/diagnosis and lab)
<b>HIV/AIDS</b>		
<b>EC-009-08</b> HIV Screening: Members at High Risk of HIV © Health Benchmarks	To ensure that members at increased risk of HIV infection be screened for HIV.	LEVEL 2 (visit/diagnosis and lab)
<b>EC-003-08</b> Appropriate Follow-up for Patients with HIV © Health Benchmarks	To ensure that all members diagnosed with HIV receive at least biannual testing for CD4 and HIV RNA levels to monitor for disease activity.	LEVEL 2 (visit/diagnosis and lab)
<b>HYPERLIPIDEMIA and ATHEROSCLEROSIS</b>		
<b>EC-203-08</b> Hyperlipidemia (Primary Prevention)- Lifestyle Changes and/or Lipid Lowering Therapy © Active Health	Percentage of patients with coronary artery disease risk factors who have an elevated LDL and who have initiated therapeutic lifestyle changes or are taking a lipid lowering agent	LEVEL 3 (lab results and patient data)
<b>EC-004-08</b> Adherence to Lipid Lowering Medication © Health Benchmarks	To ensure that members who are taking medications to treat hyperlipidemia filled sufficient medication to have at least 80% coverage during the measurement year.	LEVEL 2 (visit/diagnosis and pharmacy)
<b>EC-041-08</b> Dyslipidemia New Med 12-Week Lipid Test © Resolution Health	This measure identifies patients age 18 or older who started lipid-lowering medication during the measurement year and had a lipid panel checked within 3 months after starting drug therapy.	LEVEL 2 (pharmacy and lab)
<b>EC-217-08</b> Atherosclerotic Disease-Lipid Panel Monitoring © Active Health	Percentage of patients with coronary artery, cerebrovascular or peripheral vascular disease that have been screened for dyslipidemia with a lipid profile	LEVEL 2 (visit/diagnosis and pharmacy)
<b>EC-288-08</b> Atherosclerotic Disease and LDL Greater than 100-Use of a Lipid Lowering Agent © Active Health	Percentage of adult patients with atherosclerotic disease and an LDL greater than 100 that are taking a lipid lowering agent	LEVEL 3 (lab result)
<b>MEDICATION MANAGEMENT</b>		
<b>EC-119-08</b> Lithium Annual Creatinine Test in the ambulatory setting © Resolution Health	This measure identifies the percentage of patients taking lithium who have had at least one creatinine test after the earliest observed lithium prescription during the measurement year.	LEVEL 2 (pharmacy and lab)
<b>EC-076-08</b> Lithium Annual Lithium Test in ambulatory setting © Resolution Health	This measure identifies the percentage of patients taking lithium who have had at least one lithium level test after the earliest observed lithium prescription during the measurement year.	LEVEL 2 (pharmacy and lab)
<b>EC-077-08</b> Lithium Annual Thyroid Test in ambulatory setting © Resolution Health	This measure identifies the percentage of patients taking lithium who have had at least one thyroid function test after the earliest observed lithium	LEVEL 2 (pharmacy and lab)

Measure Number, Title and IP Owner <sup>1</sup>	Measure Description	Data Level
	prescription during the measurement year.	
<b>EC-051-08</b> Warfarin PT/ INR Test © Resolution Health		LEVEL 2 (pharmacy and lab)
<b>EC-204-08</b> Warfarin - INR Monitoring © Active Health	Percentage of patients taking warfarin with PT/INR monitoring.	LEVEL 3 (pharmacy and lab)
<b>EC-027-08</b> Ambulatory Initiated Amiodarone Therapy: TSH Test © Resolution Health	This measure identifies the percentage of patients who had a TSH baseline measurement at the start of amiodarone therapy.	LEVEL 2 (pharmacy and lab)
<b>MENTAL HEALTH and SUBSTANCE USE DISORDERS</b>		
<b>EC-014-08</b> Follow-Up After Hospitalization for Mental Illness ©NCQA	This measure assesses the percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner. Two rates are reported: Rate 1. The percentage of members who received follow-up within 30 days of discharge Rate 2. The percentage of members who received follow-up within 7 days of discharge.	LEVEL 2 (inpatient and outpatient encounters)
<b>EC-032-08</b> Bipolar antimanic agent © Resolution Health	This measure identifies the percentage of patients with newly diagnosed bipolar disorder who have received at least 1 prescription for a mood-stabilizing agent during the measurement year.	LEVEL 2 (visit/diagnosis and pharmacy)
<b>MIGRAINE</b>		
<b>EC-093-08</b> Adult(s) with Frequent Use of Acute Medications that also Received Prophylactic Medications © Ingenix	This measure identifies adults with migraines who are frequently taking acute (abortive) medications and are also taking a prophylactic medication for migraine control.	LEVEL 2 (visit/diagnosis and pharmacy)
<b>PRENATAL CARE</b>		
<b>EC-039-08</b> Diabetes and Pregnancy: Avoidance of oral hypoglycemic agents © Resolution Health	This measure identifies pregnant women with diabetes who are not taking an oral hypoglycemic agent.	LEVEL 2 (visit/diagnosis and pharmacy)
<b>EC-112-08</b> Pregnant women that had HBsAg testing © Ingenix	This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy	LEVEL 2 (visit/diagnosis and lab)
<b>EC-107-08</b> Pregnant women that had HIV testing © Ingenix	This measure identifies pregnant women who had an HIV test during their pregnancy.	LEVEL 2 (visit/diagnosis and lab)
<b>EC-110-08</b> Pregnant women that had syphilis screening © Ingenix	This measure identifies pregnant women who had a syphilis test during their pregnancy	LEVEL 2 (visit/diagnosis and lab)